Vinati Organics Q4 FY26 Earnings Call Transcript Released
Vinati Organics reported Q4 FY26 standalone PAT up 27% to ₹137 crore and full-year PAT up 18% to ₹488 crore. Consolidated EBITDA grew 13% to ₹707 crore for FY26. The company targets 15% volume growth in FY27 and plans ₹200-250 crore capex. A dividend of ₹8.50 per share is proposed.
The announcement details financial performance, future growth strategies, significant capital expenditure plans, and dividend recommendations, all of which are material information for investors and have a high impact on the company's valuation and future prospects.
The company reported strong growth in PAT and EBITDA for both Q4 FY26 and the full fiscal year. Positive outlook on future volume growth, new product development, and continued debt-free status contribute to a positive sentiment.
Vinati Organics Limited has released the transcript of its Earnings Conference Call held on May 27, 2026, to discuss the financial and operational performance for the fourth quarter and financial year ended March 31, 2026.
During the call, the company reported standalone Q4 FY26 net income growth of 17% to ₹631 crore, with EBITDA up 20% to ₹203 crore and PAT increasing by 27% to ₹137 crore. For the full year FY26, standalone EBITDA grew 17% to ₹741 crore and PAT increased 18% to ₹488 crore. On a consolidated basis, Q4 FY26 net income rose 16% to ₹624 crore, EBITDA increased 15% to ₹191 crore, and PAT grew 23% to ₹123 crore. Full year consolidated EBITDA was ₹707 crore, up 13%, and PAT increased 9% to ₹444 crore.
The company anticipates approximately 15% to 20% volume growth in FY27 for ATBS, with a target of 15% volume growth at the company level. The butyl phenols segment is expected to see moderate growth in FY27, while IB and HP-MTBE are projected for double-digit growth. The IBB volume declined by approximately 20% in FY26 due to raw material unavailability caused by the Iran war, but production is now back on track. The customized products segment grew 10% year-on-year, and the antioxidants business saw 15% revenue growth in FY26.
Capital expenditure for FY26 was approximately ₹270 crore, including investments in capacity expansion and new product development. For FY27, the company has earmarked ₹200 crore to ₹250 crore for capex. The company remains debt-free with a treasury of approximately ₹190 crore as of March 31, 2026. The Board has recommended a dividend of ₹8.50 per equity share for FY25-26, subject to shareholder approval at the AGM.
New niche chemical products are being developed for segments like fragrance, personal care, and food additives, with some revenues expected from the second half of FY27 and more significantly from FY28. The company is also exploring derivatives of MEHQ and butyl phenols, and new antioxidants. The ATBS capacity is currently operating at approximately 75% utilization. Regarding the ADD on antioxidants, the company has reapplied after the initial application was rejected, with a decision expected in 6 to 8 months.
What to do with a filing like this
Vinati Organics Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vinati Organics Limited. Read the original for the full detail.